Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for Relapsed Hematologic Malignancies Post-Transplant
NCT03286114Phase 1Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2017
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: The Number of Patients That Demonstrate Clinical Benefit From Treatment at Day 77, The Number of Patients That Respond to Treatment at Day 77 and 1 more. Started Dec 2017; status: terminated.
02
Drugs
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03286114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03286114.